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The increasing burden of chronic diseases presents not only challenges to the knowledge and expertise of the professional medical
community, but also highlights the need to improve the quality and relevance of clinical research in this domain. Many patients
now turn to complementary and integrative medicine (CIM) to treat their chronic illnesses; however, there is very little evidence
to guide their decision-making in usual care. The following research recommendations were derived from a CIM Stakeholder
Symposium on Comparative Effectiveness Research (CER): (1) CER studies should be made a priority in this field; (2) stakeholders
should be engaged at every stage of the research; (3) CER study designs should highlight effectiveness over efficacy; (4) research
questions should be well defined to enable the selection of an appropriate CER study design; (5) the CIM community should
cultivate widely shared understandings, discourse, tools, and technologies to support the use and validity of CER methods; (6)
Effectiveness Guidance Documents on methodological standards should be developed to shape future CER studies. CER is an
emerging field and its development and impact must be reflected in future research strategies within CIM. This stakeholder
symposium was a first step in providing systematic guidance for future CER in this field.
1. Introduction
The increasing burden of chronic diseases presents challenges
not only to the knowledge and expertise of the professional
medical community, but also to the socioeconomic stability
of society. Chronic disease—which includes chronic pain,
diabetes, and heart disease, among others—represents 75%
of health care spending in the USA; patients with five or more
chronic diseases account for 76% of Medicare spending [1].
Increasingly, treating patients’ chronic illnesses requires
complex interventions made up of various interconnecting
parts [2]. Especially in a combination of interventions and
the possible interactions between them, a more personalized
treatment plan is called for. Complementary and integrative
medicine is among the options that can be tailored for more
personalized/individualized medicine.
The National Center for Complementary and Alter-
native Medicine (NCCAM) defines complementary and
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alternative medicine as “a group of diverse medical and
health care systems, practices and products that are not
presently considered to be a part of conventional medicine.
Complementary medicine is used together with conventional
medicine, and alternative medicine is used in place of
conventional medicine” [3]. Its integration into health care
has shifted more and more to an “integrative medicine”
approach which was defined by the Consortium of Academic
Health Centers for Integrative Medicine as “the practice of
medicine that reaffirms the importance of the relationship
between practitioner and patient, focuses on the whole
person, is informed by evidence, and makes use of all
appropriate therapeutic approaches, healthcare professionals
and disciplines to achieve optimal health and healing” [4].
In the USA, many patients now turn to interventions
in complementary and integrative medicine to treat their
illnesses. High usage of complementary and integrative
medicine interventions, especially for patients suffering from
chronic diseases, has been reported [5]. In 2007, nearly 4
out of 10 American adults had used a complementary and
integrative medicine therapy in the previous 12 months [6].
As treatments become more complex (taking into ac-
count a patient’s local context, subgroup membership, co-
morbidities, or other factors), the design of research assessing
effectiveness requires flexibility in order to accommodate
these various factors.
Unfortunately, many complementary and integrative
medicine interventions lack the endorsement that evolves
from high quality research studies; indeed, much of the
evidence that supports their adoption has not made the
transition from the expert level into accessible, widespread
knowledge. Clearly, stakeholders (physicians, patients, pay-
ers, and others) need access to this evidence to make deci-
sions about their treatment options.
Nevertheless, research studies in complementary and
integrative medicine are on the rise. In the USA, the National
Center for Complementary and Alternative Medicine at the
National Institutes of Health and other funding agencies
and foundations have supported clinical, translational, and
basic research on the efficacy, safety, and mechanisms of
action of diverse complementary and alternative medicine
modalities. However, to date, the majority of clinical trials
have assessed the efficacy of medical interventions rather
than their effectiveness.
“Efficacy” refers to the extent to which a specific inter-
vention is beneficial under ideal conditions. By contrast,
“effectiveness” is a measure of the extent to which an inter-
vention, when deployed in the field in routine circum-
stances, does what it is intended to do for a specific
population [7]. Therefore, effectiveness can often be more
relevant to policy evaluation and the health care decisions
of providers and patients. Unfortunately, some efforts to
achieve rigorous methodological purity have resulted in
clinical results that are only marginally meaningful, because
patients, interventions, and settings are not comparable to
the real world. This burden presents the research community
with a mandate: to discover not only efficacious treatments,
but also interventions that provide the evidence critical for
decisions relevant to the treatment of usual care patients.
Drug research follows a clear hierarchical research strat-
egy that establishes efficacy before effectiveness is evaluated.
Because of its long history, complementary medicine treat-
ments are often in widespread use before clinical research
has been conducted. For complementary and integrative
medicine, a reverse research strategy was recommended [8,
9]. Using a strategy that generates evidence on comparative
effectiveness before determining component efficacy will
help to focus on treatments that have relevance for practice
and a potential for integration into health care while saving
research resources.
Because studies in Comparative Effectiveness Research
(CER) are designed to be carried out in settings that reflect
usual care, they have considerable potential to help health
care providers as well as patients and clinicians to choose
among currently available therapeutic options in comple-
mentary and integrative medicine. The Institute of Medicine
defines CER as “the generation and synthesis of evidence that
compares the benefits and harms of alternative methods to
prevent, diagnose, treat, and monitor a clinical condition or
to improve the delivery of care. The purpose of CER is to
assist consumers, clinicians, purchasers, and policy makers
to make informed decisions that will improve health care at
both the individual and population levels” [10]. (“Alterna-
tive” does not refer to “alternative medicine” but to “best
care” options.)
Among other challenges confronting the US health care
system is a paucity of information about CER [11]. The
current movement in conventional medicine towards more
CER places strong emphasis on the evaluation of different
treatment options by including more heterogeneous patients
and by using less standardized treatment protocols and
more patient-centered outcomes. Furthermore, stakeholder
involvement is seen as highly relevant [12]. Having patients,
doctors, health plan managers, hospital executives, and other
stakeholders participate in the design of CER can ensure that
this vital research focuses on the evidence gaps most relevant
to health care decision makers [13].
CER offers a wide range of research designs and advanced
techniques to distill and condense evidence from different
types of studies [14] and is not limited to randomized trials
but includes, among other options, the possibility of using
data from observational studies or registries. Additionally,
the concept of pragmatic clinical trials has emerged to
describe those randomized trials that are designed explicitly
to meet the needs of clinical and health policy decision-
making and gain increasing acceptance by decision-makers.
Because of the increasing and widespread use of interven-
tions such as acupuncture, mindfulness-based interventions
(yoga, meditation, etc.), and nutritional supplements to
manage a variety of chronic disorders (chronic pain, cardio-
vascular disorders, etc.), and because there is a significant
lack of evidence that supports decision-making regarding
these interventions, the Institute of Medicine has identified
them among its priorities for CER in complementary and
integrative medicine [10].
The aim of this project was to provide recommendations
for a strategic framework for CER in the field of complemen-
tary and integrative medicine.
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2. Methods
In 2009, The Institute of Integrative Health (TIIH) and the
Center for Medical Technology Policy (CMTP) cosponsored
a Complementary and Integrative Medicine Stakeholder
Symposium on CER. Symposium participants, including
clinicians, patient advocates, payers (health insurance com-
panies), and researchers (clinical researchers and methodol-
ogists), were selected to represent a broad range of stakehold-
ers in the field of complementary and integrative medicine.
The meeting was structured to focus attention on four
central topics: (1) current evidence gaps in complementary
and integrative medicine; (2) optimal study designs; (3) uti-
lization of CER innovations from conventional medicine for
complementary and integrative medicine; and (4) preferred
outcomes to better inform decision-making. Experts were
invited to give introductory presentations to the discussants.
Meeting participants provided helpful presentations to focus
conversation and drive discussion.
From the summary of the meeting, the following recom-
mendations for future clinical research on complementary
and integrative medicine were developed and sent back to
all meeting participants for comments [15]. Comments were
included and the final version of the recommendations was
approved by the workshop participants.
3. Recommendations
The following recommendations for future research in
complementary and integrative medicine were developed:
(1) Because Gaps in Evidence for Clinical and Health Policy
Decision-Making Are Significant, CER Studies Should Be
Made a Priority. There is widespread and increasing use of
complementary and integrative medicine, often in addi-
tion to conventional health care. Only scant evidence on
comparative effectiveness of different treatment options is
available and there are few data on the effectiveness of
complex interventions. Because of this significant lack of data
to support clinical and health policy decision-making, CER
studies are urgently needed.
(2) CER Should Engage Stakeholders at Every Stage of
Research. Stakeholders have a vested interest in the outcomes
associated with CER studies in complementary and inte-
grative medicine. Patients, payers, and clinicians and other
relevant stakeholders should be involved in every aspect
of the research including identifying research priorities,
study design, interpretation of results, and implementation.
A mechanism is needed, through which decision-makers
may communicate their needs, and that might also solicit
stakeholder input for the design and implementation of CER
studies. Patient input, in particular, can work to ensure that
studies are likely to generate patient-relevant results.
(3) CER Study Designs Should Highlight Effectiveness over
Efficacy to Support Clinical and Health Policy Decision-
Making. Designs that emphasize effectiveness over efficacy
can reshape outcomes that will be of most value to stake-
holders who are faced with decision-making in usual care
situations.
Such studies must (1) broaden the heterogeneity of
study participants; (2) report results of subgroups in study
populations even if they are exploratory; (3) ensure that
research settings—including the treatment protocol—reflect
usual care; (4) and also reflect usual practitioner-patient
interactions.
(4) Well-Defined Research Questions Are Prerequisites for
Selecting Appropriate CER Study Designs. Stakeholders in the
field of complementary and integrative medicine embrace
a vision of medicine and human health as products, pro-
cedures, pathologies, and policies enmeshed in a complex
and interdependent holistic system. Consequently, the field’s
research questions—and its need for evidence to inform
decision-making—insist that the methods used must be
appropriate to answer these research questions. Although
many methods are well established in CER, these methods
must not determine research questions, but rather, research
questions must determine methods.
A variety of study designs should be considered before
deciding which is best suited for addressing the relevant
research questions. The methodological advantages (and
disadvantages) of (1) pragmatic clinical trials; (2) cluster
randomized trials; (3) Bayesian and adaptive approaches; (4)
registries and observational studies (ideally PBRN-based);
and (5) other variants of design should be explored.
(5) The Complementary and Integrative Medicine Community
Should Cultivate Widely Shared Understandings, Discourse,
Tools, and Technologies to Support the Use and Validity of
CER Methods. Generating support for the use and validity of
methods other than RCTs requires that the complementary
and integrative medicine community continue to work with
others in the CER community to explore new study designs,
communicate results, explore decision-making, examine evi-
dence hierarchies, continuously share information, and eval-
uate its progress in meeting the goal of addressing evidentiary
gaps. The responsibility for disseminating information about
CER in complementary and integrative medicine should be
shared among stakeholders.
(6) Effectiveness Guidance Documents (EGDs) Should Be
Developed to Shape Future CER Studies. Driven by the infor-
mation and decision-making needs of patients, payers, and
clinicians and other relevant stakeholders, clear description
of the details of the design of CER studies for different
complementary and integrative medicine modalities is crit-
ical. In order to provide useful methodological guidance
for researchers, EGDs should be developed to address such
elements of study design as patient inclusion, comparators,
settings, outcomes, and/or other elements. Importantly,
EGDs can be strategically conceptualized to address specific
clinical conditions and utilize stakeholder input to ensure
that future results are applicable to real-world situations.
Because CER is continuously developing, EGDs should be
updated accordingly.
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4. Discussion
These recommendations derived from a group represent-
ing different stakeholders offer many potential benefits.
Among them are the development of research questions
clearly linked to outcomes and relevant evidence for clinical
decision-making. The development of appropriate method-
ological standards and guidance documents to interface
with CER is associated with the framework for complex
interventions [16]. Recent methodological development by
the Patient Centered Outcomes Research Institute (PCORI)
and the framework for complex interventions from UK can
provide thorough guidance [17].
These recommendations were derived from a stepwise
development process, and the active involvement of different
stakeholders (clinicians, patients, payers, and researchers)
ensures broader acceptability.
Although a consensus procedure was used to develop
these recommendations, stakeholder participation was still
limited to the group of participants. The use of more widely
disseminated survey tools to increase and diversify stake-
holder input could be leveraged in the future. Furthermore,
opinions in these recommendations derive largely from
USA-based Western perspectives and traditions. Broader
participation should be solicited from more international
experts, including non-Western experts and stakeholders.
During the development process, a broader understand-
ing of the unique methodological aspects of CER and its
applicability to complementary and integrative medicine
emerged. CER studies are intended to improve the external
validity of clinical research to enable decision-makers to
make informed decisions. Nevertheless, moving towards
higher external validity simultaneously reduces the internal
validity of study results. In a clinical trial, the balance
between internal and external validity is not a scientific
decision, but has to be carefully negotiated with the relevant
stakeholder groups. Although the recommended reverse
research strategy [8, 9] reflects the context and needs of
complementary and integrative medicine, there is a need
to discuss how contrary results on effectiveness and its
components could be transferred into clinical and health
policy decision-making.
While the phenomenon of stakeholder involvement
seems largely limited to CER studies in the United States at
present, stakeholder participation remains a high priority.
In the UK, the National Institute for Health and Clinical
Excellence (NICE) has pursued a longstanding agenda prior-
itizing community engagement [18]. Sox (2010), reporting
on the progress of CER in the US, suggested that “. . .all
stakeholders are invited to play an active role in every
aspect of CER, including priority setting, study design,
and peer review” [19]. Many stakeholders have a vested
interest in these recommendations. In that CER is now
widely discussed in the complementary and integrative
medicine community, the recommendations encourage the
development of shared understandings about the termi-
nology, methodological approaches, ethical concerns, stake-
holder engagement strategies, researcher training, and the
dissemination of CER research and discussion. CER is a
new area for complementary and integrative medicine as
it is for conventional medicine. Although, in selected areas
such as acupuncture research, some contributions to CER
have already been made, clear guidance is needed for future
research.
The recommendations provided in this paper support
the development of Effectiveness Guidance Documents
(EGDs) [20]. EGDs provide detailed guidance for researchers
who will pursue CER in the future. EGDs can focus on a
clinical condition (e.g., osteoarthritis) or a category of clini-
cal intervention (e.g., acupuncture) or both (acupuncture for
osteoarthritis). Because the quality and breadth of available
evidence varies from topic to topic, each EGD is specific
and may recommend variations in study designs, which will
generate the type and quality of evidence stakeholders need
to support decision-making.
5. Conclusion
CER is an emerging field and its development and impact
have to be reflected in future research strategy within
complementary and integrative medicine. This stakeholder
symposium was a first step in providing systematic guidance
for future CER in this field. More detailed guidance must
follow.
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